文献速递炎症性肠病

临床试验:利用铁调素和功能性铁指标预测活动性炎症性肠病患者对铁治疗的反应:一项多中心随机试验

Clinical Trial: Predicting Response to Iron Therapy in Patients With Active Inflammatory Bowel Disease Using Hepcidin and Functional Iron Indices: A Multicentre Randomised Trial.
PubMed 文献 · Aliment Pharmacol Ther · 2026-06-08

结果显示基线铁调素可预测口服铁反应(AUC 0.86),铁调素>2.68 μg/mL可识别口服铁无反应者(敏感性89%,特异性77%),高铁调素水平倾向于静脉铁治疗,低水平则提示口服铁可能有效。

要点

  • 基线铁调素可预测活动性IBD患者对口服铁的治疗反应。
  • 铁调素>2.68 μg/mL识别口服铁无反应者敏感性89%、特异性77%。
  • 高铁调素水平 favour 静脉铁,低水平提示口服铁可能有效。

核心结论

  • 基线铁调素支持铁治疗途径选择:较高水平 favour 静脉铁,较低水平提示口服铁可能有效。
  • 基于铁蛋白的指标,尤其是转铁蛋白/log10(铁蛋白),在无法检测铁调素时提供实用替代方案。

研究设计与样本

  • 12周反应定义为血红蛋白增加≥1.2 mmol/L(19.3 g/L)或IDA正常化,或铁缺乏患者铁蛋白>100 μg/L且转铁蛋白饱和度>20%。
  • 测量基线铁指标包括铁蛋白、铁调素和可溶性转铁蛋白受体(sTfR),采用逻辑回归和受试者工作特征曲线分析评估预测性能。

主要发现

  • 基线铁调素强烈预测铁治疗反应:AUC(口服富马酸亚铁):0.86,95% CI:0.71-1.00;AUC(静脉铁):0.63,95% CI:0.30-0.96。
  • 铁调素>2.68 μg/mL识别口服富马酸亚铁无反应者,敏感性89%,特异性77%。
  • 基线铁调素或铁蛋白每增加两倍,反应 odds 降低[log2(铁调素) OR:0.71,95% CI:0.56-0.89;log2(铁蛋白) OR:0.38,95% CI:0.21-0.69]。
  • 较高转铁蛋白/log10(铁蛋白)(OR:2.95,95% CI:1.38-6.30)和sTfR/log10(铁蛋白)比值(OR:1.29,95% CI:1.05-1.59)增加反应可能性。

关键数值与推荐

  • 12周反应定义:血红蛋白增加≥1.2 mmol/L(19.3 g/L)或IDA正常化,或铁缺乏患者铁蛋白>100 μg/L且转铁蛋白饱和度>20%。
  • 铁调素>2.68 μg/mL识别口服富马酸亚铁无反应者,敏感性89%,特异性77%。
  • 基线铁调素预测口服铁反应AUC 0.86(95% CI:0.71-1.00),预测静脉铁反应AUC 0.63(95% CI:0.30-0.96)。

临床怎么用

  • 基线铁调素可用于指导活动性IBD患者铁治疗途径选择:较高水平 favour 静脉铁,较低水平提示口服铁可能有效。
  • 无法检测铁调素时,可采用转铁蛋白/log10(铁蛋白)等基于铁蛋白的指标辅助预测口服铁反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Iron deficiency anaemia (IDA) is common in inflammatory bowel disease (IBD) and impairs quality of life. Hepcidin, the regulator of systemic iron homeostasis, may predict response to iron therapy; however, its utility in IBD remains unclear. This study evaluated whether baseline hepcidin predicts response to oral and intravenous (IV) iron in active IBD to guide personalised treatment. METHODS: Ninety adults with active IBD and iron deficiency (with or without anaemia) from two randomised trials received IV iron, oral ferrous fumarate (FF) or oral ferric maltol (FM). Response at 12 weeks was defined as haemoglobin increase ≥ 1.2 mmol/L (19.3 g/L) or normalisation in IDA or ferritin > 100 μg/L and transferrin saturation > 20% in iron deficient patients. Baseline iron indices including ferritin, hepcidin, and soluble transferrin receptor (sTfR) were measured. Logistic regression and receiver operating curve analyses evaluated predictive performance. RESULTS: Baseline hepcidin strongly predicted response to iron therapy: AUC(FF): 0.86, 95% CI: 0.71-1.00 and AUC(IV): 0.63, 95% CI: 0.30-0.96. Hepcidin > 2.68 μg/mL identified non-responders to FF with 89% sensitivity and 77% specificity. Each twofold increase in baseline hepcidin or ferritin reduced the odds of response [log2(hepcidin) OR: 0.71, 95% CI: 0.56-0.89; log2(ferritin) OR: 0.38, 95% CI: 0.21-0.69]. Higher transferrin/log10(ferritin) (OR: 2.95, 95% CI: 1.38-6.30) and sTfR/log10(ferritin) ratios (OR: 1.29, 95% CI: 1.05-1.59) increased likelihood of response. CONCLUSION: Baseline hepcidin supports route selection for iron therapy: higher levels favour IV iron, while lower levels indicate likely oral response. Ferritin-based indices, notably transferrin/log10(ferritin), offer pragmatic alternatives where hepcidin testing is unavailable. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05581420 and NCT05456932.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Koppelman LJM, Loveikyte R, Goetgebuer RL, et al. Clinical Trial: Predicting Response to Iron Therapy in Patients With Active Inflammatory Bowel Disease Using Hepcidin and Functional Iron Indices: A Multicentre Randomised Trial. Aliment Pharmacol Ther. 2026. PMID: 42261111. doi:10.1111/apt.70775

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。